PRQR Stock Risk & Deep Value Analysis
ProQR Therapeutics NV
DVR Score
out of 10
What You Need to Know About PRQR Stock
We analyzed ProQR Therapeutics NV using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PRQR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PRQR Risk Analysis & Red Flags
What Could Go Wrong
The Axiomer RNA editing platform, while promising, is entirely unproven in human clinical trials. A failure to demonstrate efficacy or safety in initial studies, including the upcoming H1 2026 target engagement data, would severely impact the company's valuation and likely necessitate further strategic pivots or lead to insolvency given its current lack of revenue.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
No current revenue generation, reliant on platform development.
- ⚠
Consistent net losses; Q4 2025 net loss of $9.1M.
- ⚠
High future dilution risk given cash burn and early-stage pipeline.
- ⚠
Lack of human clinical data for the Axiomer platform.
Upcoming Risk Events
- 📅
Negative or inconclusive H1 2026 target engagement data
- 📅
Significant capital raise leading to substantial shareholder dilution
- 📅
Unexpected clinical trial delays or failures for AX-0810
When to Reconsider
- 🚪
Failure of H1 2026 target engagement data to meet expectations.
- 🚪
Announcement of a capital raise that dilutes existing shareholders by more than 25%.
- 🚪
Cash runway falls below 12 months without clear progress or funding plan.
Unlock PRQR Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
ProQR Therapeutics offers a highly speculative, high-reward opportunity in the cutting-edge field of RNA editing through its Axiomer® platform. The company's strategic pivot, pipeline expansion, and partnership with Ginkgo Bioworks suggest focused execution on a promising, albeit unproven, technology. Success in early clinical milestones, particularly the H1 2026 target engagement data, could significantly de-risk the platform and unlock substantial long-term growth potential in addressing a wide range of genetic diseases.
Is PRQR Stock Undervalued?
Unlock the full AI analysis for PRQR
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PRQR Price Targets & Strategy
12-Month Target
$6.80
Bull Case
$9.00
Bear Case
$0.50
Valuation Basis
Analyst consensus median price target based on future pipeline success and platform validation, not current fundamentals.
Entry Strategy
Dollar-cost average at current levels or on dips towards $1.50, given the highly speculative nature. Position sizing should be minimal.
Exit Strategy
Take profit at analyst median price targets ($6.80, $9.00) if significant clinical milestones are met. Stop-loss at $1.00 if cash burn accelerates without progress or key data points fail.
Portfolio Allocation
1-3% for aggressive risk tolerance only.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PRQR Financially Healthy?
Valuation
P/E Ratio
-3.98
Price/Book
3.10
Price/Sales
9.62
Profitability
Operating Margin
-265.77%
Net Margin
-258.05%
Return on Equity
-66.86%
Revenue Growth
-16.36%
EPS
$-0.40
Balance Sheet
Current Ratio
3.09
Quick Ratio
3.01
Debt/Equity
0.32
Other
Beta (Volatility)
0.16
Does PRQR Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Expanding
Moat Sources
1 Identified
The durability of any moat hinges entirely on the scientific validation of the Axiomer platform through successful clinical trials and the strength of its patent portfolio. It is highly vulnerable to competitive innovations or failures in early development.
Moat Erosion Risks
- •Scientific failure of the Axiomer platform technology
- •Emergence of superior or more efficient RNA editing technologies from competitors
- •Intellectual property challenges or expiration of key patents
PRQR Competitive Moat Analysis
Sign up to see competitive advantages
PRQR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral/Slightly Bullish, driven by recent pipeline and partnership announcements rather than fundamentals.
Institutional Sentiment
Positive, with institutional ownership at 32.65% and recent analyst reiterations (Chardan, Citigroup) with price targets significantly above current levels.
Insider Activity (Form 4)
No Form 4 filings reported in the last 90 days, indicating no significant insider buying or selling.
Options Flow
Normal options activity; no specific data indicating unusual institutional positioning available in the research brief.
Earnings Intelligence
Next Earnings
2026-04-30 (Estimated Q1 2026)
Surprise Probability
Low (no consensus EPS/revenue estimates available, focus is on pipeline updates)
Historical Earnings Pattern
Historically, stock price volatility is highly correlated with pipeline news and clinical trial results, rather than quarterly financial performance for this early-stage biotech.
Key Metrics to Watch
Competitive Position
Top Competitor
VERV
Market Share Trend
Not applicable for an early-stage platform company; currently focused on establishing a market presence and demonstrating platform utility.
Valuation vs Peers
Trading at a significant discount to more advanced gene/RNA therapy companies but at a premium to its current cash/asset value due to its speculative platform potential. Analyst targets suggest substantial undervaluation if pipeline succeeds.
Competitive Advantages
- •Proprietary Axiomer® RNA editing platform technology and related IP
- •Strategic partnership with Ginkgo Bioworks for AI-driven drug discovery
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PRQR Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Expected April 30, 2026)
- •Axiomer RNA editing platform target engagement data (H1 2026)
Medium-Term (6-18 months)
- •Clinical updates for AX-0810 (Phase 2 biliary atresia)
- •Preclinical advancement of new programs AX-0811 and AX-0422
- •Expansion of Ginkgo Bioworks partnership scope or initial deliverables
Long-Term (18+ months)
- •First human clinical proof-of-concept for Axiomer RNA editing platform
- •Formation of major pharmaceutical licensing partnerships
- •Validation of the AI strategy in drug discovery and development
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PRQR?
- ✓
Positive H1 2026 target engagement data for Axiomer platform.
- ✓
Progressive clinical updates and initiation of new clinical trials for AX-0810, AX-0811, and AX-0422.
- ✓
Securing additional strategic partnerships or non-dilutive funding.
Bull Case Analysis
See what could go right with Premium
Competing with PRQR
See how ProQR Therapeutics NV compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
ProQR Therapeutics NV PRQR | $206.5M | 0.9 | -4.0 | $5.5M | -258.1% | -16.4% |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How ProQR Therapeutics NV Makes Money
ProQR Therapeutics is a biotechnology company focused on developing therapies for genetic diseases using its proprietary Axiomer® RNA editing platform. Essentially, it's a research and development firm that aims to 'correct' genetic errors in RNA to treat diseases. The company does not currently generate revenue but invests heavily in R&D to advance its pipeline of drug candidates. If successful, its business model would transition to licensing its technology to larger pharmaceutical companies, receiving milestone payments and royalties, or bringing its own drugs to market and generating revenue through sales, primarily targeting rare diseases with high unmet needs.
Read Full Business Model BreakdownFAQ
What is the DVR Score for ProQR Therapeutics NV (PRQR)?
As of April 21, 2026, ProQR Therapeutics NV has a DVR Score of 0.9 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of ProQR Therapeutics NV?
ProQR Therapeutics NV's market capitalization is approximately $206.5M..
What is the risk level for PRQR stock?
Our analysis rates ProQR Therapeutics NV's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PRQR?
ProQR Therapeutics NV currently has a price-to-earnings (P/E) ratio of -4.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is ProQR Therapeutics NV's revenue growing?
ProQR Therapeutics NV has reported revenue growth of -16.4%. Revenue has been declining, which warrants closer examination.
Is PRQR stock profitable?
ProQR Therapeutics NV has a profit margin of -258.1%. The company is currently unprofitable.
How often is the PRQR DVR analysis updated?
Our AI-powered analysis of ProQR Therapeutics NV is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PRQR (ProQR Therapeutics NV) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.